ARTBIO
Develops alpha radioligand therapies (ARTs) for targeted cancer treatment with resilient supply chain.
Develops alpha radioligand therapies (ARTs) for targeted cancer treatment with resilient supply chain.
Sector
Life SciencesCategory
TherapeuticsLocations
Basel, SwitzerlandCambridge, MA
Oslo, Norway
London, UK
Initial Investment
2021ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). ARTBIO’s approach uses the optimal alpha-emitting isotope (Pb212) with tumor-specific targets to create unique radioligand therapeutics. The company’s AlphaDirectTM technology, a first-of-its-kind Pb212 isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs.
